Literature DB >> 18803760

Impaired CD4 and CD8 T cell phenotype and reduced chemokine secretion in recent-onset type 1 diabetic children.

M Hedman1, M Faresjö, S Axelsson, J Ludvigsson, R Casas.   

Abstract

Although the role of the T cell-mediated autoimmune reaction in type 1 diabetes (T1D) is conclusive, studies including data from human circulating CD4(+) and CD8(+) lymphocytes subsets during the disease onset and posterior development are scarce. Further, chemokines and chemokine receptors are key players in the migration of pathogenic T cells into the islets of non-obese diabetic mice developing T1D, but few studies have investigated these markers in human T1D patients. We studied the expression of T helper 1 (Th1)- and Th2-associated chemokine receptors, and the two isoforms of CD45 leucocyte antigen on CD4(+) and CD8(+) lymphocytes from T1D and healthy children, as well as the secretion of chemokines in cell supernatants in peripheral blood mononuclear cells. Our results showed increased expression of CCR7 and CD45RA and reduced CD45RO on CD8(+) cells among recent-onset T1D patients. The percentages of CD4(+) cells expressing CXC chemokine receptor 3 (CXCR3), CXCR6 and CCR5, and the secretion of interferon-gamma-induced protein-10, monocyte chemoattractant protein-1, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta was lower among diabetics. Low expression of Th1-associated receptors and secretion of chemokines, together with an increased amount of CD8(+) cells expressing CD45RA and CCR7 in T1D patients therefore might represent suboptimal Th function in T1D, leading to impaired T cytotoxic responses or alternatively reflect a selective recruitment of Th1 cells into the pancreas.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18803760      PMCID: PMC2527367          DOI: 10.1111/j.1365-2249.2008.03720.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  51 in total

1.  CCR4-bearing T cells participate in autoimmune diabetes.

Authors:  Soon H Kim; Mary M Cleary; Howard S Fox; David Chantry; Nora Sarvetnick
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

2.  Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential.

Authors:  C H Kim; E J Kunkel; J Boisvert; B Johnston; J J Campbell; M C Genovese; H B Greenberg; E C Butcher
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

3.  Cytokine expression in unstimulated PBMC of children with type 1 diabetes and subjects positive for diabetes-associated autoantibodies.

Authors:  M Halminen; O Simell; M Knip; J Ilonen
Journal:  Scand J Immunol       Date:  2001-05       Impact factor: 3.487

4.  The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3.

Authors:  P Loetscher; A Pellegrino; J H Gong; I Mattioli; M Loetscher; G Bardi; M Baggiolini; I Clark-Lewis
Journal:  J Biol Chem       Date:  2000-11-10       Impact factor: 5.157

5.  Tolerance to islet antigens and prevention from diabetes induced by limited apoptosis of pancreatic beta cells.

Authors:  Stéphanie Hugues; Evelyne Mougneau; Walter Ferlin; Dirk Jeske; Paul Hofman; Dirk Homann; Lucie Beaudoin; Corinne Schrike; Matthias Von Herrath; Agnès Lehuen; Nicolas Glaichenhaus
Journal:  Immunity       Date:  2002-02       Impact factor: 31.745

6.  Elevated serum IP-10 levels observed in type 1 diabetes.

Authors:  A Shimada; J Morimoto; K Kodama; R Suzuki; Y Oikawa; O Funae; A Kasuga; T Saruta; S Narumi
Journal:  Diabetes Care       Date:  2001-03       Impact factor: 19.112

7.  Reduced expression of Th1-associated chemokine receptors on peripheral blood lymphocytes at diagnosis of type 1 diabetes.

Authors:  T Lohmann; S Laue; U Nietzschmann; T M Kapellen; I Lehmann; S Schroeder; R Paschke; W Kiess
Journal:  Diabetes       Date:  2002-08       Impact factor: 9.461

8.  Serum concentrations of the interferon-gamma-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease.

Authors:  F Nicoletti; I Conget; M Di Mauro; R Di Marco; M C Mazzarino; K Bendtzen; A Messina; R Gomis
Journal:  Diabetologia       Date:  2002-06-21       Impact factor: 10.122

Review 9.  Autoreactive CD8 T cells in organ-specific autoimmunity: emerging targets for therapeutic intervention.

Authors:  Roland S Liblau; F Susan Wong; Lennart T Mars; Pere Santamaria
Journal:  Immunity       Date:  2002-07       Impact factor: 31.745

10.  Phenotypic characterisation of T-lymphocytes in COPD: abnormal CD4+CD25+ regulatory T-lymphocyte response to tobacco smoking.

Authors:  B Barceló; J Pons; J M Ferrer; J Sauleda; A Fuster; A G N Agustí
Journal:  Eur Respir J       Date:  2007-12-05       Impact factor: 16.671

View more
  13 in total

Review 1.  Natural killer cell memory.

Authors:  Silke Paust; Ulrich H von Andrian
Journal:  Nat Immunol       Date:  2011-06       Impact factor: 25.606

2.  Altered proportions of naïve, central memory and terminally differentiated central memory subsets among CD4+ and CD8 + T cells expressing CD26 in patients with type 1 diabetes.

Authors:  Elena Matteucci; Massimo Ghimenti; Serena Di Beo; Ottavio Giampietro
Journal:  J Clin Immunol       Date:  2011-09-02       Impact factor: 8.317

3.  Low expression of CD39(+) /CD45RA(+) on regulatory T cells (Treg ) cells in type 1 diabetic children in contrast to high expression of CD101(+) /CD129(+) on Treg cells in children with coeliac disease.

Authors:  K Åkesson; A Tompa; A Rydén; M Faresjö
Journal:  Clin Exp Immunol       Date:  2015-04       Impact factor: 4.330

4.  Advances and challenges in biomarker development for type 1 diabetes prediction and prevention using omic technologies.

Authors:  Colleen Carey; Sharad Purohit; Jin-Xiong She
Journal:  Expert Opin Med Diagn       Date:  2010-09-01

5.  Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies.

Authors:  Simona Cernea; Kevan C Herold
Journal:  Clin Immunol       Date:  2010-02       Impact factor: 3.969

6.  Evaluation of in vivo T cell kinetics: use of heavy isotope labelling in type 1 diabetes.

Authors:  J B Bollyky; S A Long; M Fitch; P L Bollyky; M Rieck; R Rogers; P L Samuels; S Sanda; J H Buckner; M K Hellerstein; C J Greenbaum
Journal:  Clin Exp Immunol       Date:  2013-06       Impact factor: 4.330

Review 7.  Obstacles and opportunities for targeting the effector T cell response in type 1 diabetes.

Authors:  Jane H Buckner; Gerald T Nepom
Journal:  J Autoimmun       Date:  2016-03-03       Impact factor: 7.094

8.  Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes.

Authors:  Stina Axelsson; Mikael Chéramy; Maria Hjorth; Mikael Pihl; Linda Akerman; Emanuela Martinuzzi; Roberto Mallone; Johnny Ludvigsson; Rosaura Casas
Journal:  PLoS One       Date:  2011-12-12       Impact factor: 3.240

9.  High Risk First Degree Relatives of Type 1 Diabetics: An Association with Increases in CXCR3(+) T Memory Cells Reflecting an Enhanced Activity of Th1 Autoimmune Response.

Authors:  Tanja Milicic; Aleksandra Jotic; Ivanka Markovic; Katarina Lalic; Veljko Jeremic; Ljiljana Lukic; Natasa Rajkovic; Dušan Popadic; Marija Macesic; Jelena P Seferovic; Sandra Aleksic; Jelena Stanarcic; Milorad Civcic; Nebojsa M Lalic
Journal:  Int J Endocrinol       Date:  2014-03-23       Impact factor: 3.257

10.  Decreased CD127 expression on CD4+ T-cells and elevated frequencies of CD4+CD25+CD127- T-cells in children with long-lasting type 1 diabetes.

Authors:  Marcin Moniuszko; Barbara Glowinska-Olszewska; Malgorzata Rusak; Marta Jeznach; Kamil Grubczak; Danuta Lipinska; Robert Milewski; Anna Justyna Milewska; Milena Dabrowska; Ewa Jablonska; Adam Kretowski; Maria Gorska; Anna Bodzenta-Lukaszyk; Artur Bossowski
Journal:  Clin Dev Immunol       Date:  2013-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.